Advanced Search Results For "Davis, Avram"
Your filters
Epigenome-wide DNA methylation association study of circulating IgE levels identifies novel targets for asthmaResearch in context
Publication Type: Academic Journal
Source(s): EBioMedicine, Vol 95, Iss , Pp 104758- (2023)
Abstract: Summary: Background: Identifying novel epigenetic signatures associated with serum immunoglobulin E (IgE) may improve our understanding of molecular mechanisms underlying asthma and IgE-mediated diseases. Methods: We performed an epigenome-wide associa...
Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial
Publication Type: Periodical
Source(s): The Lancet; May 2023, Vol. 401 Issue: 10387 p1499-1507, 9p
Abstract: Low-dose corticosteroids have been shown to reduce mortality for patients with COVID-19 requiring oxygen or ventilatory support (non-invasive mechanical ventilation, invasive mechanical ventilation, or extracorporeal membrane oxygenation). We evaluated...
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis
Publication Type: Periodical
Source(s): The Lancet; July-August 2022, Vol. 400 Issue: 10349 p359-368, 10p
Abstract: We aimed to evaluate the use of baricitinib, a Janus kinase (JAK) 1–2 inhibitor, for the treatment of patients admitted to hospital with COVID-19.
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publication Type: Periodical
Source(s): The Lancet; February 2022, Vol. 399 Issue: 10325 p665-676, 12p
Abstract: Casirivimab and imdevimab are non-competing monoclonal antibodies that bind to two different sites on the receptor binding domain of the SARS-CoV-2 spike glycoprotein, blocking viral entry into host cells. We aimed to evaluate the efficacy and safety o...
Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publication Type: Periodical
Source(s): The Lancet; January 2022, Vol. 399 Issue: 10320 p143-151, 9p
Abstract: Aspirin has been proposed as a treatment for COVID-19 on the basis of its anti-thrombotic properties. We aimed to evaluate the efficacy and safety of aspirin in patients admitted to hospital with COVID-19.
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial
Publication Type: Periodical
Source(s): The Lancet; May-June 2021, Vol. 397 Issue: 10289 p2049-2059, 11p
Abstract: Many patients with COVID-19 have been treated with plasma containing anti-SARS-CoV-2 antibodies. We aimed to evaluate the safety and efficacy of convalescent plasma therapy in patients admitted to hospital with COVID-19.
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publication Type: Periodical
Source(s): The Lancet; May 2021, Vol. 397 Issue: 10285 p1637-1645, 9p
Abstract: In this study, we aimed to evaluate the effects of tocilizumab in adult patients admitted to hospital with COVID-19 with both hypoxia and systemic inflammation.
Comparison of Two Nasal Cell Collection Methods in Determining Cyclic Adenosine Monophosphate Levels and its Association with Olfaction: A Feasibility Study
Publication Type: Academic Journal
Source(s): Allergy & Rhinology, Vol 5 (2014)
Abstract: Cyclic adenosine monophosphate (cAMP) is a second messenger that may be associated with olfactory function. No known studies have compared existing collection methods for determining nasal cAMP levels. This is a prospective study comparing the comfort ...
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
Publication Type: Periodical
Source(s): The Lancet; February 2021, Vol. 397 Issue: 10274 p605-612, 8p
Abstract: Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatory actions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Publication Type: Periodical
Source(s): The Lancet; July 2019, Vol. 394 Issue: 10193 p121-130, 10p
Abstract: Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c(HbA1c) concentrations. We assessed the effect of the GLP-1 re...